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 Mitochondrial fatty acid oxidation (FAO) plays an important role in 
maintaining metabolic homeostasis, especially during catabolic stress.  Genetic 
mutation in gene that encodes for mitochondrial FAO enzymes could result in 
metabolic stress especially during fasting or hypoglycemic condition. Mutation in 
the active site residue (1528G>C) of long chain 3-hydroxy acyl CoA 
dehydrogenase (LCHAD) results in the loss of LCHAD enzyme activity.  
Children’s with LCHAD mutation were known to accumulate 3-hydroxy fatty acids 
such as 3-hydroxy palmitic acid and 3-hydroxy myristic acids, long chain free 
fatty acids, acyl carnitine and 3-hydroxy dicarboxylic acid due to their defective 
enzyme activity. These accumulated 3-hydroxy fatty acids and long chain free 
fatty acids are toxic compound to the cellular tissues and results in the 
development of retinopathy. Here we hypothesize that increased levels of 3-
hydroxy fatty acid due to a mutation in LCHAD would induce retinal pigment 
epithelial cell lipoapoptosis and palmitoleate (PO) protects against 3-hydroxy 
fatty acid-induced retinal lipoapoptosis. Normal human immortalized retinal 
pigment epithelial cells (ARPE-19) were treated with 3-hydroxy fatty acid (3-HFA) 
for 24 hours and biochemical markers of lipoapoptosis such as characteristic 
nuclear morphological changes of apoptosis and caspase 3/7 activity were 
measured. Mitochondrial bioenergetics were assessed using Seahorse XF24 
extracellular flux analyzer and lipid droplets were stained with oil red ‘O’ dye. 
After 24-hours of 3-HFAs treatment to ARPE-19 cells, we observed a significant 
increase in percent apoptotic nuclei and caspase 3/7 activity compared to the 
vehicle treated cells suggesting retinal lipoapoptosis. Further, percent cell 
survival and metabolic activity were decreased in cells treated with 3-HFA 
compared to vehicle treatment. 3-HFA-induced retinal cell lipoapoptosis is cJun 
N-terminal kinase- and caspase-dependent lipoapoptosis. Treatment of 3-HFAs 
to retinal cells showed decreased mitochondrial bioenergetics as evidenced by a 
decrease in basal respiration, ATP production, maximal respiration and 
mitochondrial coupling efficiency compared to vehicle (p <.05). We also observed 
that PO protects against 3-HFA-induced retinal lipoapoptosis. However further 
investigations are required to understand the mechanism of palmitoleate 
protection. In conclusion, 3-HFAs induce lipid droplet accumulation and 
mitochondrial stress resulting in retinal pigment epithelial cell lipoapoptosis, 
which was protected with PO supplementation.  
i 
 
Dedication 
 This thesis is dedicated to my family, especially my parents, Kassem and 
Barqiah, my husband, Haitham, and my daughters, Seba and Dema. 
 
 
  
ii 
 
List of Abbreviations and Symbols 
 
FAs Fatty acids 
FAO Fatty acid oxidation 
FAODs Fatty acid oxidation disorders 
MTP Mitochondrial trifunctional protein 
SCAD Short-chain acyl-CoA dehydrogenase 
MCAD Medium-chain acyl-CoA dehydrogenase 
LCHAD Long-chain 3-hydroxy acyl-CoA dehydrogenase 
VLCAD Very long-chain acyl-CoA dehydrogenase 
CPT-II Carnitine palmitoyl transferase 2 
LCHADD Long-chain 3-hydroxy acyl-CoA dehydrogenase deficiency 
DNA Deoxyribonucleic acid 
DRs Death receptors 
TNF Tumor-necrosis factors 
AIF Apoptosis-inducing factor 
ROS Reactive oxygen species 
ATP Adenosine Triphosphate 
OXPHOS Oxidative phosphorylation 
MPT Mitochondrial permeability transition 
HMG-CoA Hydroxy-3-methylglutaryl-coenzyme-A 
MAPK Mitogen-activated protein kinase 
FoxO3 Forkhead family of transcription factor class O3 
iii 
 
3-HFA 3-Hydroxy fatty acid 
3-HMA 3-Hydroxy myristic acid 
3-HPA 3-Hydroxy palmitic acid 
RPE Retinal pigmented epithelium 
CPT Carnitine palmitoyl transferase 
hiPSC Human-induced pluripotent stem cell 
MCFT Medium chain fatty acids 
PA Palmitic acid 
MA Myristic acid  
PO Palmitoleic acid 
SFA Saturated free fatty acid 
LDL Low-density lipoprotein 
HDL High-density lipoprotein 
DMEM Dulbecco's Modified Eagle's Medium 
FBS Fetal bovine serum 
BSA Bovine serum albumin 
PARP Poly (ADP-ribose) polymerase 
DAPI 4′,6-diamidino-2-phenylindole 
PUMA p53 upregulated modulator of apoptosis 
BORC Biomedical and Obesity Research Core 
OCR Oxygen consumption rate 
PBS Phosphate buffered saline 
NADH Nicotinamide adenine dinucleotide 
iv 
 
ECAR Extracellular acidification rate 
SEM Standard error of Mean 
ANOVA Analysis of variance 
  
 
  
v 
 
 
Acknowledgements 
 I would like to express my sincere appreciation to my advisor Dr. Sathish 
Kumar Natarajan for his support and guidance in conducting this research, I 
could not be more appreciative. 
 I also want to thank Dr. Seung-Hyun Ro and Dr. Jiujiu Yu for agreeing to 
serve on my supervisory committee. I am grateful for their mentorship in guiding 
this research. 
 I also would like to thank the staff in Biomedical and Obesity Research 
Core (BORC) facility for using their equipment for mitochondria stress and Dr. 
Chung facility in which I used the light microscope for my experiments.  
 I would also like to acknowledge my colleagues and lab mates Mr. 
Ezhumalai Muthukrishnan, Mr. Prakash Sahoo, Mrs. Philma-Glora Muthuraj, Mrs. 
Madison Kraus, Mrs. Jillian Power, and Mrs. Taylor Bruett for their help, 
cooperation, support, and most importantly friendship. Thanks to King Abdullah 
scholarship program (Saudi Arabia) for financially supporting my studies at UNL. 
Thanks for National Institute of Health, General Medical Sciences, and Nebraska 
Center for the Prevention of Obesity Disease, P20GM104320. 
 Finally, I owe my sincere gratitude and gratefulness to my family, 
especially my parents, Kassem Hadidi and Barqiah Al-Ardi, my husband, 
Haitham Hadidi, and daughters, Seba and Dema for their endless support and 
encouragement. Special thanks to my parents for the endless support and 
prayers and to husband and daughters for their support and patience that 
vi 
 
enabled me to pursue my studies. I love you all. You stand behind me firmly, and 
together we have experienced many joyous moments and endured many 
stressful occasions. You are the light, source, and motivation for my dreams. 
  
vii 
 
Table of Contents 
DEDICATION ........................................................................................................ i 
LIST OF ABBREVIATIONS AND SYMBOLS ...................................................... ii 
ACKNOWLEDGEMENTS .................................................................................... v 
LIST OF TABLES ............................................................................................... ix 
LIST OF FIGURES ............................................................................................... x 
1. CHAPTER I: INTRODUCTION ......................................................................... 1 
1.1 Fatty Acid (FA) Metabolism .................................................................... 2 
1.1.1 Mitochondrial Fatty Acid Oxidation ............................................... 3 
1.1.2 Fatty Acid Oxidation Disorders (FAODs) ...................................... 4 
1.1.3 Long Chain 3-Hydroxy Acyl-CoA Dehydrogenase Deficiency 
(LCHAD) ..……………………………………………………………………….5 
1.2 Apoptosis ................................................................................................. 6 
 1.2.1 Extrinsic and Intrinsic Pathway of Apoptosis .............................. 8 
1.3 Mitochondria ............................................................................................ 9 
1.3.1 Mechanisms of Mitochondria in Inducing Pathophysiology ..... 10 
  1.3.2 Role of Mitochondria in Fatty Acid Oxidation Disorders ........... 12 
1.4 Retinal Pigmented Epithelial Cells in LCHAD Deficiency .................. 14 
1.4.1 Apoptosis of Retinal Cells in LCHAD Deficiency ............................ 15 
1.5 Dietary Supplementation as a Protective Strategy against LCHAD 
Deficiency ……………………………………………………………………..16 
1.5.1 Medium Chain Fatty Acids (MCFA) Supplementation ............... 16 
1.5.2 Carnitine Supplementation .......................................................... 17 
1.5.3 Docosahexaenoic acid (DHA) supplementation......................... 17 
 1.5.4 Protection Role of Palmitoleate Supplementation ……...………18 
1.6 Central Hypothesis, Purpose, and Specific Aims............................... 20 
1.6.1 Central Hypothesis and Purpose ................................................. 20 
1.6.2 Specific Aims ................................................................................ 21 
 
2. CHAPTER II: MATERIALS AND METHODS ................................................. 22 
2.1 Cell Culture ............................................................................................ 22 
2.1.1 Sub-culturing Cells ....................................................................... 22 
2.1.2 Counting Cells............................................................................... 22 
2.1.3 Cell Seeding .................................................................................. 23 
2.2 Fatty Acids Preparations ...................................................................... 23 
2.2.1 Treatment of 3-Hydroxy Fatty Acids (3-HFA).............................. 24 
2.3 Apoptotic Nuclear Morphological Changes ........................................ 25 
2.4 Measurements of Caspase 3/7 Activity ............................................... 25 
2.5 Mitochondrial Stress ............................................................................. 26 
2.5.1 Platting Cultures and Hydrating Sensor Cartridge .................... 26 
viii 
 
2.5.2 Preparing Assay Medium ............................................................. 27 
2.5.3 Preparing Stock Compounds....................................................... 27 
2.5.4 Running XF Assay and Measuring Oxygen Consumption Rate 
(OCR) ...................................................................................................... 28 
2.6 Western Blotting.................................................................................... 28 
2.6.1 Protein Isolation ............................................................................ 28 
2.6.2 Protein Estimation ........................................................................ 28 
2.6.3 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) Gel and Immunoblot Analysis ........................................ 29 
2.6.4 Immunoblot Detection .................................................................. 30 
2.7 Oil Red O staining ................................................................................. 30 
2.8 Measuring Cell Survival Using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) Assay .............................................. 31 
2.9 Z-VAD and JNK inhibitors .................................................................... 31 
2.10 Statistical Analysis.............................................................................. 31 
 
3. CHAPTER III: RESULTS ............................................................................... 32 
3.1 Results ................................................................................................... 32 
3.1.1 Treatment of 3-Hydroxy Palmitic Acids (3-HPA) Decreased 
Mitochondrial Bioenergetics in Retinal Pigmented Epithelial Cells 
(ARPE-19) ............................................................................................... 32 
3.1.2 3-Hydroxy Fatty Acids (3-HFAs) Induce Retinal Pigment 
Epithelial Cell (ARPE-19) Lipoapoptosis ............................................. 35 
3.1.3 Saturated Free Fatty Acids Palmitic Acid (PA) and Myristic Acid 
(MA) Did not Induce in ARPE-19 Lipoapoptosis ................................. 40 
3.1.4 Biochemical Hallmark of Apoptosis ............................................ 46 
3.1.5 Palmitoleic Acid (PO) Protects Against 3-HFA-Induced 
Lipotoxicity ............................................................................................. 47 
3.1.6 Retinal Cells Accumulated Lipid Droplet with 3-HPA or 3-HMA 
Treatment………………………………………………………………………50 
3.1.7 3-HFA-Induces Retinal Cell Lipoapoptosis is c-Jun N-Terminal 
Kinase Activation ................................................................................... 53 
3.1.8 3-HFA Induces Retinal Cell Lipoapoptosis is Caspase 
Dependent……………………………………………………………………..54 
 
CHAPTER IV: DISCUSSION, CONCLUSION, AND FUTURE DIRECTIONS ... 58 
4.1 Discussion: ............................................................................................ 58 
4.2 Conclusions and Future Directions ..................................................... 65 
REFERENCES ................................................................................................... 66 
 
 
ix 
 
List of Tables 
1.1 Comparison of Fatty Acids Oxidation Pathways ........................................ 2 
  
x 
 
 
List of Figures 
Fig. 1. The extrinsic and intrinsic apoptotic pathways. At the plasma 
membrane, extrinsic pathway is activated when death receptors 
ligands bind to a subset of tumor necrosis factor receptor (TNF) 
receptors including TNFR1, Fas receptor, and death receptors. 
These receptors activate the procaspases 8 and 10 which leads to 
the activation of caspase 3 and 7 resulting in apoptosis. Intrinsic 
pathway is modulated by cell stressors such as Endoplasmic 
reticulum stress, DNA damage, nutritional stress and hypoxia. 
Mitochondrial outer membrane permeabilization (MOMP) occurs via 
the interaction of pro-apoptotic BH3 containing proteins such as 
BAX and BAK and BAX/BAK oligomerization. Pro-apoptotic 
intermembrane space (IMS) releases Cytochrome c (Cyt c) and 
second mitochondria-derived activator of caspase (SMAC) resulting 
in activating procaspase 9. Active caspase 9 cleaves pro-caspase 3 
and 7 resulting in their activation for caspase-dependent apoptosis. 
This figure is adopted and modified from (Kalkavan & Douglas, 
2017).......................................................................................................... 7 
 
Fig. 2. Mitochondrial dysfunction provoked by fatty acids and acyl 
carnitines accumulating in FAOD. In defective fatty acid oxidation 
(FAO) pathway, the acyl-CoA can’t be converted into Acetyl-CoA 
resulting in higher accumulation of the substrates such as acyl 
carnitines and fatty acids. The accumulation of these compounds is 
toxic to the heart, liver, muscle, and brain tissue’s that relay on fatty 
acids for energy. This lipotoxicity alters the mitochondrial 
bioenergetic functions and increases oxidative stress. This figure is 
adopted from (Wajner & Umpierrez, 2016) .............................................. 11 
 
Fig. 3. Schematic of (a) Hematocytometer and (b) counting chamber ................ 23 
 
Fig. 4. 24-well plate of a control and 3-HFA treated ARPE-19 cells .................... 24 
 
Fig. 5. Schematic representation of SDS-PAGE gel and loading wells ............... 29 
 
xi 
 
Fig. 6. Mitochondrial bioenergetics functions in ARPE-19 cells treated with 
3-HPA. A) Oxygen consumption rate (OCR) for 100 minutes in 
vehicle and 3-HPA treated ARPE-19 cells. B) Basal respiration (B), 
Maximal respiration (C), ATP production (D), Coupling efficiency 
(E), Spare respiratory capacity (F) , and Proton Leak of ARPE-19 
cells treated with 3-HPA and compared with vehicle ARPE-19 cells, 
respectively* indicates P-value with different level of significance 
compared to vehicle treatment, *(<0.05). ** (<0.01), and 
***(<0.001). The data is represented mean ± SEM from five 
independent experiments, n=5.The statistical significance of the 
observed differences were obtained by analysis of variance 
(ANOVA) and Tukey post-hoc test. .......................................................... 33 
 
Fig. 7. Representative phase contrast and fluorescent DAPI stained live 
cell images of ARPE-19 cells with 3-HPA treatment. This 
representative figure shows that 3-hydroxy palmitic acids (3-HPA) 
induced nuclear morphological changes in retinal pigment epithelial 
cell (ARPE-19) lipoapoptosis. (A and B) are vehicle cells. (C-H) are 
ARPE-19 cells were treated with different concentrations of 3-HPA 
(100, 200, and 250 µM). Scale bar represents 200 μM............................ 37 
 
Fig. 8. Representative phase contrast and fluorescent DAPI stained live 
cell images of ARPE-19 cells with 3-HMA treatment. This 
representative figure shows that 3-hydroxy myristic acids (3-HMA) 
nuclear morphological changes in in retinal pigment epithelial cell 
(ARPE-19) lipoapoptosis. (A and B) are vehicle cells. (C-H) are 
ARPE-19 cells were treated with different concentrations of 3-HMA 
(100, 200, and 250 µM). Scale bar represents 200 μM.. .......................... 38 
 
Fig. 9. Evidence for cell death in APRE-19 cells with 3-HFA treatment. A) 
Apoptotic nuclei percent for ARPE-10 cells treated with different 
concentrations of 3-hydroxy myristic acid (3-HMA) (100- 250 µM) 
and B) Cells treated with 3-hydroxy palmitic acid (3-HPA) (100-250 
µM). C) Caspase 3/7 activity represented as fold change in ARPE-
19 cells treated with 3-HMA D) cells treated with 3-HPA. E and F) 
Percent cell survival of ARPE-19 with different concentrations of 3-
HMA or 3-HPA treatment. * indicates P-value with different level of 
significance, *(<0.05). ** (<0.01), and ***(<0.001). The differences 
in the apoptotic changes reached a statistical significance by 
obtaining that using ANOVA and Tukey test. ........................................... 40 
 
xii 
 
Fig.10 Representative Phase contrast and fluorescent DAPI stained live 
cell images of ARPE-19 cells with MA treatment. This 
representative figure shows that myristic acids (MA) did not 
increased staining of DAPI suggesting no change in characteristics 
of nuclear morphological changes in in retinal pigmented epithelial 
cell (ARPE-19) lipoapoptosis. (A and B) are vehicle cells. (C, D, E, 
F, G, H, I and J) ARPE-19 cells were treated with different 
concentrations of MA (100, 150, 200, and 250 µM). Scale bar 
represents 200 μM ................................................................................... 42 
 
Fig.11 Representative Phase contrast and fluorescent DAPI stained live 
cell images of ARPE-19 cells with PA treatment. This 
representative image show that palmitic acids (PA) did not increase 
staining of DAPI suggesting no change in characteristics of nuclear 
morphological changes in in retinal pigment epithelial cell (ARPE-
19) lipoapoptosis. (A and B) vehicle treated cells. (C, D, E, f, G, H, I 
and J) ARPE-19 cells were treated with different concentrations of 
PA (100, 150, 200, and 250 µM). Scale bar represents 200 μM. ............. 44 
 
Fig.12 Apoptotic nuclei percent for ARPE-10 cells treated with different 
concentrations of myristic acid (MA) (100-250 µM) (A) and ARPE-19 
cells treated with different concentrations of palmitic acid (PA) (100-
250 µM) (B). Caspase 3/7 activity in ARPE-19 cells treated with MA (C) 
and PA (D). * indicates P-value with different level of significance, 
*(<0.05). ** (<0.01), and *** (<0.001)... .................................................... 45 
 
Fig.13 Immunoblot analysis of Cleaved PARP, PUMA, Cleaved Caspase 
3, and Actin in vehicle and 3-HPA/3-HMA treated ARPE-19 cells. 
Vehicle cells were isopropanol treatment and 3-HPA (250 µM) or 3-
HMA (250 µM) treated cell lysates were analyzed after 12, 18, and 
24 hours of treatment. .............................................................................. 47 
 
Fig.14 Apoptotic cell death and caspase activation in ARPE-19 cells 
treated with 3-HPA or 3-HMA along with palmitoleate. Apoptotic 
nuclei percent for ARPE-19 cells treated with 3-HMA and PO (A) 
and cells treated with 3-HPA and PO (B). Caspase 3/7 activation in 
ARPE-19 cells treated with 3-HMA and PO (C) and cells treated 
with 3-HPA and PO (D). Percent cell survival of ARPE-19 cells with 
3-HMA (E) or 3-HPA (F) with and without palmitoleate (PO). Data 
represents mean ± SEM from five independent experiments, n=5. * 
indicates P-value with different level of significance of 3-HPA or 3-
xiii 
 
HMA compared to vehicle, *(P<0.05). ** (P<0.01), and 
***(P<0.001). #P>0.05 compared to 3-HPA or 3-HMA. ............................ 49 
 
Fig.15 Lipid droplet accumulation for ARPE-19 cells. Cells stained with Oil 
red O’ assay visualized under light microscope. Control cells were 
treated with Vehicle (A) and Palmitoleate (B). Retinal cells with 250 
μM of 3-HMA (C) and 3-HPA treatment (E) for 24 hours showed 
increased Oil red ‘O’ staining. Co-treatment of palmitoleate (PO) 
with of 250 µM 3-HPA or 3-HMA (D and F) resulted in decreased 
Oil red ‘O’ staining. The images are representative images from 
three independent experiments, n=3. ...................................................... 52 
 
Fig.16 Oil red O’ assay absorbance in ARPE-19 cells.  ARPE-19 cells 
treated with only 3-HMA (250 µM) and both 3-HMA (250 µM) and 
PO (200 µM) (A). Cells treated with 3-HPA (250 µM) alone and co-
treated with 3-HPA (250 µM) and PO (200 µM) (B). * indicates P-
value with different level of significance of 3-HPA or 3-HMA 
compared to vehicle, *(<0.05). ** (<0.01), and ***(<0.001). # 
indicates P-value for 3-HPA or 3-HMA with PO compared to 3-HPA 
or 3-HPA  ................................................................................................. 53 
 
Fig.17 Caspase 3/7 activity and percent cell survival in ARPE-19 cells 
treated with JNK-i. Caspase 3/7 activity were measured when cells 
were treated with 3-HMA and co-treated with 3 HMA and JNK 
inhibitor (SP600125, JNKi) (A) or treated with only 3-HPA or co-
treated with 3-HPA and JNK-i. (B). Percent cell survival were 
measured when cells were treated with only 3-HMA or co-treated 
with 3-HMA JNKi (C) and only 3-HPA and co-treated with 3-HPA 
and JNKi (D). Data represent mean ± SEM from five independent 
experiments, n=5. *indicates P-value with different level of 
significance of 3-HPA or 3-HMA compared to vehicle (veh), 
*(<0.05). ** (<0.01), and ***(<0.001). # P<0.05 compared to 3-HMA 
or 3-HPA treatment ……………………………………………………...55  
 
Fig.18 Caspase 3/7 activity and percent cell survival in ARPE-19 cells 
treated with Z-VAD. Caspase 3/7 activity were measured when 
cells were treated with 3-HMA and co-treated with 3 HMA and 
caspase inhibitor (Z-VAD fmk) (A) or treated with only 3-HPA or co-
treated with 3-HPA and Z-VAD (B). Percent cell survival were 
measured when cells were treated with only 3-HMA or co-treated 
with 3-HMA Z-VAD (C) and only 3-HPA and co-treated with 3-HPA 
and Z-VAD (D). Data represent mean ± SEM from five independent 
xiv 
 
experiments, n=5. *indicates P-value with different level of 
significance of 3-HPA or 3-HMA compared to vehicle (veh), 
*(<0.05). ** (<0.01), and ***(<0.001). # P<0.05 compared to 3-HMA 
or 3-HPA treatment …………………………………………………56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
1. CHAPTER I: INTRODUCTION 
 
1.1 Fatty Acid (FA) Metabolism 
 Metabolism is the set of chemical reactions that occur within living cells in 
order to convert food into energy for the cellular processes (catabolism) and to 
convert small nutrients into larger molecules (anabolism). In living organisms, 
fatty acids (FAs) are essential components and building blocks for cellular 
membranes and provide energy for the body. Fat lipolysis is the biochemical 
process that takes place in the cytoplasm where the large fatty molecules such 
as triglycerides can be broken down and hydrolyze into glycerol and three 
molecules of fatty acids (FAs) in which enters mitochondria for its metabolism. 
The FAs are metabolized by three types fatty acid oxidation pathways such as 
mitochondrial-β oxidation, microsomal ω- oxidation and peroxisomal beta-
oxidation, these pathways are different from each other and these differences are 
illustrated if Table 1. Mitochondrial β-oxidation is the most important pathway in 
living organisms which oxidizes the released FAs into two carbon units of acetyl 
CoA. Fatty acid oxidation (FAO) occurs with help of multiple enzymatic reactions. 
Translocation of fatty acids across the mitochondrial outer and inner membrane 
were carried out with the help of carnitine palmitoyl-transferase I and II (CPT 
I&II). Long-chain fatty acyl-carnitine enters the mitochondrial outer membrane by 
binding to carnitine via CPT-I and CPT-II translocase that transfer the fatty acyl-
carnitine into the mitochondrial matrix, where Beta-oxidation pathway takes 
place. In this pathway, two carbons are cleaved from the long-chain acyl-CoA to 
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form acetyl-CoA by breaking the bond between beta carbon and gamma carbon. 
Thus, formed acetyl-CoA can enter tricarboxylic acid cycle in the mitochondrial 
matrix.  
 
Table 1 Comparison of Fatty Acids Oxidation Pathways 
 
 
Beta- 
Oxidation 
Omega-
Oxidation 
Peroxisome-
Oxidation 
Location 
Mitochondrial 
matrix for all 
tissues except 
erythrocyte and 
adrenal medulla 
Microsomes Peroxisome 
Substrate 
Long, medium, 
short chain fatty 
acids 
Long and very 
long fatty 
acids 
Bile acids 
intermediates, very 
long fatty acids 
Benefits 
Major pathway to 
maintain 
mitochondrial 
homeostasis and 
production of 
ATP 
Oxidation of 
omega 
carbon, when 
beta-oxidation 
defect, this 
pathway 
becomes 
active 
Oxidation of the beta 
carbon of the fatty 
acyl CoA molecule 
Deficiencies 
HADHA 
deficiency 
Systemic 
carnitine 
deficiency, 
carnitine cycle 
disorder 
--------- 
Zellweger syndrome 
X-linked 
adrenoleukodystrophy 
(X-ALD), Acyl-CoA 
oxidase deficiency 
(ACOX1) deficiency, 
diastolic blood 
pressure (DBP) 
deficiency 
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1.1.1 Mitochondrial Fatty Acid Oxidation 
 Mitochondrial β-oxidation is the predominant FA oxidation pathway for 
cellular energy needs, plays an important role in maintaining metabolism 
homeostasis, especially during catabolic stress situations such as infection, 
disease, exercise, and fasting conditions. A large number of fatty acid oxidation 
disorders (FAODs) have been associated with a genetic defect in enzymes 
involved in fatty acid oxidation pathways (Wilcken, 2010). Mitochondrial 
trifunctional protein (MTP) is one of the complex enzymes that is required for the 
mitochondrial fatty acid oxidation (FAO). MTP is a multi-enzyme complex located 
in the mitochondrial inner membrane as a hetero-octamer and it contains four 
subunits: alpha-subunits and four beta-subunits. Alpha subunit contains enoyl-
CoA hydratase and 3-hydroxyacyl-CoA dehydrogenase activity and beta subunit 
has 3-ketoacyl CoA thiolase activity. The oxidation involves four main enzymes 
and they are acyl-CoA dehydrogenase, enoyl-CoA hydratase and 3-hydroxyacyl-
CoA dehydrogenase, and thiolase respectively. Any deficiency in one of these 
enzymes results in blockage of FAO process leading to fatty acids oxidation 
disorders. FAO is highly active in major metabolic organs like heart, liver and 
muscle cells and therefore FAO disorders that are associated with beta-oxidation 
are mostly expressed in the organs that relay on FAs metabolism predominantly 
affects liver, heart, and muscles (Wajner & Umpierrez, 2016).  
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1.1.2 Fatty Acid Oxidation Disorders (FAODs) 
 FAODs are inherited metabolic diseases that are classified as inborn 
errors metabolism. FAODs are autosomal recessive genetic disorders which are 
caused as result of defects in genes that encodes mitochondrial FAO enzymes. 
The incidence of FAODs is about 1 in every 10,000 individuals (Merritt, Norris, & 
Kanungo, 2018).  There are more than fifteen different FAODs, the most 
common disorders are short-chain acyl-CoA dehydrogenase (SCAD), medium-
chain acyl-CoA dehydrogenase (MCAD), long-chain 3-hydroxy acyl-CoA 
dehydrogenase (LCHAD), and very long-chain acyl-CoA dehydrogenase 
(VLCAD) deficiency (Wajner & Umpierrez, 2016). The four most common 
enzyme deficiencies are carnitine palmitoyl transferase 2 (CPT-II), very long-
chain acyl-CoA dehydrogenase (VLCAD), long-chain 3-hydroxyacyl-CoA 
dehydrogenase (LCHAD), and mitochondrial trifunctional protein (MTP). 
Individuals with FAOD accumulate toxic compounds in their circulations such as 
fatty acids and fatty acyl-carnitine. These disorders can be diagnosed in early 
stage of newborn life through laboratory analysis by measuring the levels of free 
fatty acids, dicarboxylic acid, and acyl-carnitine metabolites in blood and urine 
sample using Tandem Mass Spectrometry and Gas Chromatography (Enns et 
al., 2000). 
 Newborns who are diagnosed with FAOD usually have a multi-organ 
failure with a wide range of severity such as fatigue, hypoglycemia, 
rhabdomyolysis, hepatopathy, cardiomyopathy, and skeletal myopathy. These 
symptoms are mostly associated and worsened by fasting, infection, cold 
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exposure, exercise, infections, and other catabolic situations that require a high 
energy usage. Majority of the studies have indicated that the most associated 
reason for pathophysiology in FAODs is energy deficiency. Further,  
accumulating evidence that indicate the role of toxic fatty acids and fatty acyl 
carnitine metabolites in disturbing mitochondrial homeostasis which results in the 
development of most pathophysiology of FAODs (Wajner & Umpierrez, 2016).  
 
1.1.3 Long Chain 3-Hydroxy Acyl-CoA Dehydrogenase Deficiency (LCHAD) 
 Long-chain 3-hydroxy acyl-CoA dehydrogenase deficiency (LCHAD) is a 
disorder that is characterized by lack in LCHAD enzyme activity that is required 
for fatty acid β-oxidation in the mitochondria. The incidence of LCHAD mutation 
is 1:50,000 newborns (Hagenfeldt, Venizelos, & Von Dobeln, 1995). LCHAD is 
inherited disorder that has homozygous mutation in HADHA gene c.1528G>C 
affecting LCHAD enzyme activity (Padmini et al., 2015). As a result of this 
disorder, the body can’t utilize long-chain fatty acids resulting in their 
accumulation as acyl-carnitine and long chain fatty acids in the systemic 
circulation. 
 Clinical presentations of LCHAD deficiency involves pathologies of the 
organs that relay on the mitochondria for energy supply including heart, muscle, 
liver, and eye. LCHAD deficient individuals usually present with common 
features; hypoglycemia, metabolic acidosis, skeletal myopathy, hypotonia, 
cardiomyopathy and hepatic steatosis, adipose tissue accumulation, retinopathy, 
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exercise intolerance and neuropathy (Wilcken, 2010) (Waisbren, Landau, Wilson, 
& Vockley, 2013).  
 
1.2 Apoptosis 
 Apoptosis is a programmed cell death process that maintains cell 
homeostasis during growth and development by eliminating severely damaged 
cells. In early phase of apoptosis, mitochondria activate the release of caspases 
by initiating caspase cascade resulting in pro-apoptotic signaling as a death 
response (Solary, Bertrand, Kohn, & Pommier, 1993) (Gavrieli, Sherman, & Ben-
Sasson, 1992). Caspases are found as inactive proenzymes, during apoptosis, 
the activation of the caspase is required to cleave many proteins out of the 
mitochondrial membrane. After caspase activation, morphological changes occur 
like cell shrinkage, nuclei condensation, and DNA fragmentation. Then, vital 
caspase substrates in the cells is cleaved by the active caspase’s resulting in the 
release of apoptotic bodies, which spread rapidly as a result of phagocytosis of 
neighboring cells. Apoptosis occurs primarily via two main pathways namely 
extrinsic and intrinsic pathway of apoptosis as illustrated in Figure 1. Both 
pathways are initiated by different mechanisms and signals which activate the 
caspases 3 and 7 that cleave more than 1000 proteins leading to changes in cell 
morphology indicating apoptosis (Kalkavan & Douglas, 2017).  
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Figure 1  The extrinsic and intrinsic apoptotic pathways. At the plasma 
membrane, extrinsic pathway is activated when death receptors ligands bind to a 
subset of tumor necrosis factor receptor (TNF) receptors including TNFR1, Fas 
receptor, and death receptors. These receptors activate the procaspases 8 and 
10 which leads to the activation of caspase 3 and 7 resulting in apoptosis. 
Intrinsic pathway is modulated by cell stressors such as Endoplasmic reticulum 
stress, DNA damage, nutritional stress and hypoxia. Mitochondrial outer 
membrane permeabilization (MOMP) occurs via the interaction of pro-apoptotic 
BH3 containing proteins such as BAX and BAK and BAX/BAK oligomerization. 
Pro-apoptotic intermembrane space (IMS) releases Cytochrome c (Cyt c) and 
second mitochondria-derived activator of caspase (SMAC) resulting in activating 
procaspase 9. Active caspase 9 cleaves pro-caspase 3 and 7 resulting in their 
activation for caspase-dependent apoptosis. This figure is adopted and modified 
from (Kalkavan & Douglas, 2017). 
Active caspase 9 
Pro-caspase 9 
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1.2.1 Extrinsic and Intrinsic Pathway of Apoptosis 
 The extrinsic pathway or death receptors pathway of apoptosis is initiated 
by the activation of death receptors (DRs) at cell membrane including tumor-
necrosis factors (TNF), TNFR1, Fas receptor, CD95, and TRAIL receptors, 
respectively. These receptors play a critical role in communicating death signals 
from cell surface into mitochondria (Saraste, 1999). Once the subset of these 
receptors is activated by ligand binding in the plasma membrane, the activation 
of procaspase-8 or 10 takes place leading to their substrate caspase 3 and 7 
cleavage and activation for the induction of apoptosis.  
  The intrinsic pathway of apoptosis is a response to internal damage and 
stressors such as damaged DNA, damaged chromosome, and ER- stress. As a 
result of the cell sensation to the internal stressors, the interaction of BCL-2 
family members such as the activation of BH3 domain containing pro-apoptotic 
proteins; BAX and BAK, and results in the formation of mitochondrial outer 
membrane permeabilization pore (MOMP). Consequently, the releases of 
apoptogenic factors such as cytochrome c, second mitochondria-derived 
activator of caspases (SMAC) (Kroemer et al., 2009) and apoptosis-inducing 
factor (AIF) from the mitochondria are induced (Kalkavan & Douglas, 2017; 
Saraste, 1999) . These proteins induce caspase dependent and independent cell 
death by generating reactive oxygen species (ROS) and cytochrome which 
eventually trigger caspase 3 activation. The activated caspases cleave proteins 
that stimuli apoptosis and result in abnormalities in genome DNA. However, both 
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intrinsic and extrinsic pathways activate caspase cascade leading to programed 
cell death. 
 
1.3 Mitochondria 
 Mitochondria is an important organelle to maintain cellular homeostasis, to 
produce adenosine triphosphate (ATP), to regulate redox and calcium 
homeostasis, cellular metabolism, and apoptosis. Mitochondria has unique 
function for lipid metabolism where fatty acids oxidation takes place. The integrity 
and the quality of mitochondria are controlled through many cellular and 
molecular pathways (Radek et al., 2014).Mitochondria is considered as a clock 
that affect the lifespan of cellular processes, any disturbance in the mitochondrial 
function can result in the development of metabolic disorders (Blagosklonny, 
2008). Defect in mitochondrial performance results in altered redox hemostasis 
leading to the generation of reactive oxygen species (ROS) (Radek, Marco, & 
Heinz, 2014). Further, mitochondria have also been demonstrated to regulate 
intracellular signaling via Ca2+ and ROS (Tait & Green, 2012). Abnormal levels 
of ROS generation can impact the mitochondrial processes causing a disruption 
in respiratory chain, and activate apoptotic process (Friedman & Jodi, 2014). It is 
important to control mitochondrial integrity to maintain cellular homeostasis. The 
manifestation of a variety of human diseases can impair the quality control 
system of the mitochondria.  
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1.3.1 Mechanisms of Mitochondria in Inducing Pathophysiology 
 In LCHAD disorder, the mitochondria are involved in mechanisms of 
inducing apoptosis and lipotoxicity. Although energy deficiency seems to play a 
major role in development of pathophysiology especially in hepatopathy 
cardiomyopathy of the affected patients (Wilcken et al., 2007)and skeletal 
myopathy (Spiekerkoetter et al., 2010), central and peripheral neuropathy are not 
associated with caloric intake and hypoglycemia (Wajner & Umpierrez, 2016). 
Therefore, it is possible that there are mechanisms other than energy deficiency 
could contribute to the pathogenesis of LCHAD deficiency. It has been suggested 
that mitochondrial stress and accumulation of metabolites compounds such as 
fatty acids and carnitine might be the mechanisms that induce pathogenesis in 
LCHAD deficient individuals (Spiekerkoetter & Wood, 2010); (Olpin, 2013).  
 Wajner et al., summarized the recent evidences of the mechanisms that 
affect energy homeostasis and lead to pathophysiology. The gathered data was 
based on patients and animal models with mitochondrial disorders suggesting 
that the mechanisms to disorders might be redox reactions, fatty acid 
accumulation, calcium homeostasis, and energy deficiency.  Figure 2 illustrates 
the major roles of accumulated fatty acids metabolites inducing lipotoxicity 
resulting in energy and mitochondrial damage (Wajner & Umpierrez, 2016). 
LCHAD deficient individuals develop mitochondrial dysfunction and energy 
deficiency. Further, biochemical and mitochondrial morphological alterations 
were also observed in LCHAD deficient patients’  heart, skin fibroblasts, and 
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muscle tissues (Derks et al., 2014);( Najdekr et al., 2015);( Feillet et al., 
2003);(Wakabayashi et al., 2012); (Ruitenbeek et al., 1995). 
 
Figure 2 Mitochondrial dysfunction provoked by fatty acids and acyl 
carnitines accumulating in FAOD. In defective fatty acid oxidation (FAO) 
pathway, the acyl-CoA can’t be converted into Acetyl-CoA resulting in higher 
accumulation of the substrates such as acyl carnitines and fatty acids. The 
accumulation of these compounds is toxic to the heart, liver, muscle, and brain 
tissue’s that relay on fatty acids for energy. This lipotoxicity alters the 
mitochondrial bioenergetic functions and increases oxidative stress. This figure is 
adopted from (Wajner & Umpierrez, 2016). 
 
Further, oxidative phosphorylation (OXPHOS) takes a place in the 
mitochondria to produce ATP and reactive oxygen species (ROS) through 
respiration chain. The ROS plays an important role in regulating gene and 
enzyme activity, increased free radical production and decreased ATP-
production would lead the cells to a cascade of apoptosis or necrosis (Natarajan, 
Eapen, Pullimood, & Balasubramanian, 2006). Collectively, these published 
evidences ensure how mitochondria and energy disturbance are associated with 
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pathophysiology in the tissues that primarily relay on the mitochondrial fatty acid 
β-oxidation like LCHAD deficient patients.  
  
1.3.2 Role of Mitochondria in Fatty Acid Oxidation Disorder 
 Individuals with LCHAD deficiency accumulate lipotoxic compounds such 
as fatty acids and acyl carnitines in the systemic circulation and tissues which 
might induce cellular lipotoxicity (Lipoapoptosis). There are many evidences 
supporting the role of accumulated fatty acids and acyl carnitines compounds in 
distressing mitochondrial homeostasis mainly on the brain, liver, and skeletal 
muscle. Meyer et al., isolated retinal cells from early forebrain populations and 
they used hiPSC cultures showing that excessive lipid load in non-adipose cells 
such as retinal pigmented epithelial (ARPE) cells can impair normal cell signaling 
leading to peroxidation, cellular dysfunction, and apoptotic cell death (Meyer et 
al., 2011). Although non-adipose cells such as ARPE cells have limited capacity 
for lipid storage, LCHAD deficient retinal cells have shown lipid accumulation 
resulting in retinal atrophy (Meyer et al., 2011). Further, medium-chain acyl-CoA 
deficiency (MCAD) results in the accumulation of medium fatty acids like octanoic 
acid, decanoic acid, and cic-4-decanoic acid. These accumulated medium chain 
fatty acids results in mitochondrial damage and induces BAX-BAK 
oligomerization resulting in pore formation in the mitochondrial outer membrane 
and alters the mitochondrial permeability transition (mPT) (Parker, W., Haas, 
Stumpf, & Eguren, 1983); (Schuck, Ferreira Gda et al., 2009); (Schuck et al., 
2010); (Schuck, Ferreira et al., 2009). Wajner et al, postulated that LCHAD 
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deficient accumulate 3-hydroxy fatty acids like 3-hydroxydodecanoic acid, 3-
hydroxy myristic acid, and 3-hydroxy palmitic acid.  Further, in LCHAD deficient 
animals, it was shown that hydroxy fatty acids can disturb energy and redox 
homeostasis (Wajner & Umpierrez, 2016). These hydroxy fatty acids were shown 
to uncouple mitochondrial oxidative phosphorylation (OXPHOS), induces mPT 
and oxidative stress leading to the pathophysiology of cardiac, hepatic, and 
myopathic in LCHAD deficient individuals. In addition to hydroxy fatty acids, 
carnitine derivatives also accumulate in tissue causing disturbance to the 
mitochondria and Ca+2 homeostasis (Wajner & Umpierrez, 2016). Further, 
lipotoxic lipid metabolites induces mitochondrial abnormalities leading to many 
events including uncoupling of OXPHOS, decreases respiratory chain activity, 
and nicotinamide adenine dinucleotide (NAD+) levels (Touma & Charpentier, 
1992); (Trauner, Nyhan, & Sweetman, 1975).  
Our lab has previously published that long-chain fatty acids e.g., palmitic 
acid and arachidonic acid were elevated during acute fatty liver of pregnancy 
(AFLP) or LCHAD deficiency. We also have unpublished data on the mechanism 
of 3-hydroxy fatty acid-induced hepatocyte lipoapoptosis (Natarajan & Ibdah, 
2018). Further, our lab has also established the lipotoxic role of palmitic acid in 
causing hepatocyte and cholangiocyte lipoapoptosis by the activation of mitogen-
activated protein kinase (MAPK), and forkhead family of transcription factor class 
O3 (FoxO3) dependent pro-apoptotic signaling pathway (Natarajan et al., 2014); 
(Natarajan et al., 2017). Another study demonstrated that the major accumulating 
lipotoxic metabolites during LCHAD deficiency is 3-hydroxymyristic acid (3-HMA) 
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and 3-hydroxypalmatic acid (3HPA) in the circulation and these 3-hdyroxy fatty 
acids were also found to accumulated in different tissues, and significantly affects 
mitochondrial homeostasis (Hickmann et al., 2015). Collectively, it has been 
demonstrated that the lipotoxicity of 3-hydroxy fatty acids and acyl carnitine 
metabolites were more likely to be involved in the pathogenesis of LCHAD 
deficient individuals.   
 
1.4 Retinal Pigmented Epithelial Cells in LCHAD Deficiency 
 Retinal pigmented epithelium (ARPE) is a monolayer of cells that are the 
main nutrient provider for the retina in eye. Melanin display potential antioxidant 
roles including inhibition of oxidation, remove redox-active metal ions, and 
protect against free radicals in retinal pigment epithelium (RPE). Development of 
retinopathy is highly associated with LCHAD deficiency but not with other fatty 
acid oxidation disorders (FAODs) (Padmini et al., 2015). The LACHD inherited 
deficiency has been reported to develop pigmentary retinopathy leading to vision 
loss without early intervention, high myopia, poor vision, and chorioretinal 
atrophy (Tyni et al., 1998). Tyni et al., have also demonstrated the fatty acid 
oxidation enzymes in retinal pigment epithelial cells including carnitine palmitoyl 
transferase (CPT-I and CPT-II) and all mitochondrial beta-oxidation enzymes 
(Tyni, Paetau, Strauss, Middleton, & Kivela, 2004).   
 The pigmentation in RPE tends to decrease with aging leading to vision 
degradation (Padmini et al., 2015) and patients with LCHAD deficiency develop 
different stages of pigment retinopathy (Tyni, Immonen, Lindahl, Majander, & 
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Kivela, 2012). Further, severity of retinopathy and staging for chorioretinopathy 
were documented in LCHAD deficient individuals. The RPE of patient with 
LCHAD deficiency at early stage showed retinopathy with less pigmentation and 
less atrophy. The RPE of patient with LCHAD in advance stage displayed severe 
retinopathy, dramatic pigmentation and damage in the retinal cells. However, the 
mechanism behind the retinopathy in LCHAD deficiency is still unclear. Also, it 
has been suggested that the accumulation of toxic long chain fatty acids (LCFA) 
and 3-hydroxy fatty acids (3-HFA) might be a possible mechanism behind 
retinopathy (Den et al., 2002);(Schrijver-Wieling et al., 1997). Based on this 
literature we hypothesized that defective mitochondrial fatty acid β-oxidation and 
the accumulation of 3-hydroxy fatty acid in the retinal epithelium can induce the 
development retinopathy in LCHAD deficient individuals.    
 
1.4.1 Apoptosis of Retinal Cells in LCHAD Deficiency 
 Padmini et al., has isolated human induced pluripotent stem cell (hiPSC) 
from LCHAD deficient individuals and differentiated hiPSC into RPE cells to 
create LCHAD deficient in vitro culture model (Padmini et al., 2015). These cells 
were derived from patients with homozygotes mutation in HADHA gene. The 
study compared control RPE cells to the cells derived from LCHAD deficient 
individuals and characterized the RPF cell structure and functional alterations. 
The differentiated RPE from LCHAD deficient individuals displayed increased 
lipid accumulation, less pigmentation, few melanosomes, retinal atrophy and 
increased RPE apoptosis. They also observed mitochondrial damage and 
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decreased mitochondrial oxidant scavenging are potential as a mechanism of 
retinopathy. In summary, PRE cells from patients with LCHAD deficiency showed 
mitochondrial damage increased lipid accumulation, decreased melanosome, 
and apoptosis. 
 
 
1.5 Dietary Supplementation as a Protective Strategy Against LCHAD 
Deficiency  
 The main strategy for patients with LCHAD deficiency is to avoid energy 
complications. Dietary management of LCHAD involves long chain fatty acids 
(LCFA) restrictions and avoids  catabolic crises such as fasting by giving 
adequate supply of calories from carbohydrate and medium chain fatty acids 
(MCFA) (Wajner & Umpierrez, 2016). However, giving glucose polymers is not 
recommended to be supplemented habitually, instead, oral prophylactic is 
suggested for emergency treatment (Spiekerkoetter et al., 2009). To prevent or 
slow the progression of chorioretinopathy and other pathologies that are 
associated with LCHAD deficiency, patients are recommended to follow a very 
low-fat diet (10% of total energy) supplemented with medium chain fatty acids 
(MCFA) (10% of energy) (Wajner & Umpierrez, 2016).  
 
1.5.1 Medium Chain Fatty Acid (MCFA) Supplementation 
Exercise requires higher energy supply, it has been reported that MCFA 
supplementation is enough to provide sufficient energy for prolonged period of 
exercise in patients with very long-chain acyl-CoA deficiency (VLCAD) 
(Spiekerkoetter, 2007). Therefore, supplementing with MCFA is important for 
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optimal health needs for VLCAD deficient individuals (Lindner et al., 2009). 
Further, the destruction of muscle cells that are resulted from exercise can be 
inhibited by taking adequate amount of MCFA before the exercise in LCHAD 
deficient individuals (Gillingham, Scott, Elliott, & Harding, 2006). Since the fat 
intake is restricted, patients with LCHAD need to be supplemented with fat-
soluble vitamins. In addition, Triheptanoin (UX007) is a drug composed of 
medium chain triglyceride that possesses the gluconeogenic and ketogenic role 
because it provides alternative substrates during increased energy needs and 
during fasting. It has been shown that UX007 can reduce hypoglycemia, 
rhabdomyolysis, and cardiac functions and improves endurance exercise and 
tolerance in patients with severe LCHAD deficiency (Vockley et al., 2017).  
 
1.5.2 Carnitine Supplementation 
Carnitine supplementation might be beneficial for detoxification of the toxic 
3-hydroxy fatty acids and long chain fatty acids compounds from the circulation 
(Spiekerkoetter & Wood, 2010). On other hand, L-carnitine was found to worsen 
the health by accumulating toxic long-chain carnitine substrates (Treem et al., 
1996); (Rocchiccioli et al., 1990). However, further study needs to be explored to 
understand the protective role of carnitine against lipotoxic 3-hydroxy fatty acids 
metabolites in retinal pigment epithelial cells. 
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1.5.3 Docosahexaenoic Acid Supplementation  
 The beneficial role of docosahexaenoic acid (DHA) has been explored in a 
prospective cohort study for the retinal function in children’s with LCHAD 
deficiency.  The authors demonstrated that DHA-supplemented patients with 
LCHAD deficiency showed reduced the retinal complications (Gillingham, 
Weleber, & Neuringer, 2005).It was also demonstrated that the severe 
progression of chorioretinopathy was associated in patients with elevated 3-
hydroxy-acylcarnitines. Further, levels of 3-hydroxyacylcarnitines and 3-hydroxy 
fatty acids were directly proportional with severity of retinal atrophy (Gillingham et 
al., 2005); (Jones et al., 2000); (Jones et al., 2001).  These data suggest the 
3-hydroxy fatty acids is toxic to the retina and RPE cells and supports our 
hypothesis of the present study.   
 The dietary recommendations for LCHAD deficient patients highlighted in 
the previous sections are still not a mechanism based. Additionally, many 
patients still experiencing hospitalization due to shortage in energy supply and 
accumulation of toxic 3-hydroxy fatty acids compounds (Kinman et al., 2006; Roe 
& Brunengraber, 2015). Our long-term goal is to develop a nutraceutical 
approach to prevent 3-hydroxy fatty acid-induced retinal pigment epithelium 
damage. 
 
1.5.4 Protective Role of Palmitoleate Supplementation  
 Palmitoleic acid (PO) is a monounsaturated omega-7 fatty acid that 
present in animal fat, plant oil, and macadamia nuts. It can be synthesized from 
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palmitate C16 (saturated fatty acid) by the enzyme stearoyl CoA-desaturase 
(SCD1). PO is involved in many processes associated with cell function such as 
growth, signaling, storage, and cell differentiation. It has been demonstrated that 
PO acts as anti-apoptotic fatty acid that improves lipid profile in metabolic 
disease animal models (Morgan, Dhayal, Diakogiannaki, & Welters, 2008); 
(Morgan & Dhayal, 2010). Zhi-Hong Yang et al. showed antidiabetic effect of PO 
in KK-Ay mice that developed diabetes and hyperglycemia. Further, PO enriched 
diet has been demonstrated to protect pancreatic beta cells from apoptosis, 
improved hypertriglyceridemia, glycemic control, glucose uptake, and  prevented 
lipid accumulation in the liver in KK-Ay mice (Yang, Z. H., Miyahara, & Hatanaka, 
2011). In comparison to palmitic acid (PA) a saturated fatty acids,  PO has more 
protective role against hepatic lipotoxicity and placental lipotoxicity (Yang, H., 
Miyahara, & Hatanaka, 2011); (Yang, Z. H. et al., 2011). Additionally, Yang et al., 
investigated in animals by orally administered vehicle (control), 300 mg/kg per 
day of PA, or 300 mg/kg per day PO for 4 weeks to show the effect of palmitoleic, 
acid on hepatic steatosis in KKAy mice. PO dramatically reduced lipid 
accumulation in the liver of diabetic mice compared to control and PA 
supplementation. In addition, PO supplementation also controlled lipogenesis 
and prevented lipid accumulation in adipose tissue 
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1.6 Central Hypothesis, Purpose, and Specific Aims 
1.6.1 Central Hypothesis and Purpose 
 Retinopathy is very common characteristic in patients with LCHAD 
deficiency that is not observed in other fatty acid oxidation defects. The retinal 
damage in LCHAD deficient patients is associated with retinal pigmentation, 
peripheral neuropathy, and cognitive deficiency (Tyni, Paetau, Strauss, 
Middleton, & Kivela, 2004) (Natarajan & Ibdah, 2018). However, the molecular 
mechanism behind the retinopathy in LCHAD deficiency still unclear.  
 Identification of the lipotoxic role of 3-hydroxy fatty acids (3-HFAs) may 
offer new perspectives for potential mechanism and to develop new therapeutic 
dietary strategies to LCHAD deficient patients. Hence, we hypothesize that the 
increased levels of toxic 3-hydroxy fatty acid metabolites in LCHAD deficiency 
can induce lipoapoptosis in retinal pigment epithelial cells. Despite the dietary 
recommendations for patients with LCHAD with medium chain fatty acids 
(MCFAs) supplementation, patients still experiencing hospitalization due to 
shortage in energy supply and accumulation of toxic 3-HFAs metabolites. 
Because MCFAs can be elongated to form long chain fatty acids (LCFAs). 
Therefore, future prospective studies and development of approved treatment 
strategies are needed. In terms of nutritional or dietary therapy, it has been 
shown that palmitoleic acid (PO) has a beneficial role against lipid accumulation 
in liver of diabetic mice and it also plays a protective role against hepatic lipid 
droplets accumulations. We further hypothesized that PO protects against 
3-HFAs induced retinal pigmented epithelial (RPE) cells lipoapoptosis. 
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 This master thesis underlines how the accumulated 3-hydroxy fatty acids 
(3-HFAs) contribute to retinal pigment epithelial cell damage. To further 
understand the mechanism of the damage, this study aimed to identify the 
molecular mechanism of the 3-HFA-induced retinal pigment epithelial cell 
lipotoxicity using human immortalized adults retinal pigmented epithelial cells 
(ARPE-19).  Further, the protective role of palmitoleic acid (PO) in reducing lipid 
accumulation in retinal cells is also investigated. Further the role of p53 
upregulated modulator of cJun N-terminal kinase (JNK) in 3-HFAs-induced RPE 
lipoapoptosis is also investigated.  
 
1.6.2 Specific Aims 
The specific research objectives of this thesis are as follows: 
• Specific Aim 1: We will determine the mitochondrial bioenergetics of 
retinal pigmented epithelial cells (ARPE-19) cells with 3-HFAs exposure.  
• Specific Aim 2: We will detect the role of 3-HFAs in inducing cell 
apoptosis in ARPE-19.  
• Specific Aim 3: We will detect the lipid droplet accumulation in ARPE-19 
cells with 3-HFAs treatment.  
• Specific Aim 4: We will elucidate the mechanism of 3-HFA-induced 
ARPE cell lipoapoptosis is via caspase and JNK activation.  
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2. CHAPTER II: MATERIALS AND METHODS 
 
2.1 Cell Culture 
2.1.1 Sub-Culturing Cells  
 Cell cultures were performed using normal human retinal pigmented 
epithelial cells (ARPE-19) that were purchased from ATCC. The ARPE-19 were 
grown as monolayer in medium Dulbecco's Modified Eagle's Medium (DMEM) 
containing serum-supplement with 10% of FBS (fetal bovine serum), HEPES (4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (15 mM) , sodium pyruvate 
(0.5 mM) , and sodium bicarbonate (1200 mg/L).  The cells were seeded in flask 
with growth media and cultured in an environment with 5% CO2 at 37 °C. For 
sub-culturing the cells; media was discarded using aspirator, the cells were 
rinsed with PBS and incubated 1 mL of Trypsin for 1-2 minutes to allow the cells 
to detach from the flask. After that, 5 mL of growth media was added, and cells 
were re-suspended and cell suspension were centrifuged 500 x g for 5 minutes 
to remove the supernatant and the cell pellets were resuspended with fresh 
media and platted in new culture flask.  
 
2.1.2 Counting Cells  
  The cells were counted using hemocytometer was placed under the 
microscope with 10X objective to visualize the cells located in the chambers 
indicated by gridlines square. Figure 3 (A) shows a schematic of the location of 
the counted cells inside the chamber.  After counting the cells in both chambers, 
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the cells were averaged then multiplied by the following factors: dilution factor 
(10X), mL-conversion factor (1000), and number of squares that contained 
counted cells as shown in Figure 3 (B).  
 
 
Figure 3   Schematic of (A) Hematocytometer and (B) counting chamber. 
 
2.1.3 Cell Seeding  
  ARPE-19 cells were seeded at density of 60,000 cells/well in 24-well plate 
and 10,000 cells/well in 96-well plate containing DMEM media with volume of 
500 µL/well in 24-well plate and 100 µL/well in 96-well plate, respectively. 
Treatment of different 3-hydroxy fatty acids or fatty acids were performed after 
the cells were attached to the plate.  
   
2.2 Fatty Acids Preparations 
 Different types of fatty acids were used in the present study: 3-hydroxy 
fatty acids (3-hydroxy palmitic acid and 3-hydroxy myristic acid), saturated fatty 
acids (palmitic acid and myristic acid), and palmitoleic acid were treated as 
described below.  
   
  
  
Induction port 
Chamber 1 
Chamber 2 
Cover glass 1 2 
4 5 
3 
(A) 
(B) 
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2.2.1 Treatment of 3-Hydroxy Fatty Acids (3-HFA) 
 The experiment was designed with two different conditions including a 
vehicle control and 3-HFAs treatment. The vehicle cells were treated with only 
isopropanol and 1% of bovine serum albumin (BSA) obtained from Millipore 
Sigma. The ARPE-19 cells were treated with two different types of 3-HFA: 
3-hydroxy palmitic acid (3-HPA) and 3-hydroxy myristic acid (3-HMA), both were 
purchased from Cayman Chemical Company. These 3-hydroxy fatty acids were 
dissolved in isopropanol with a stock solution of 80 µM. To treat the cells with 3-
HFA, 1% BSA containing growth media were preincubated at 37°C for 30 
minutes and filter sterilized. BSA-containing media was is mixed with 3-HFA and 
incubated at 37°C for another 20 minutes prior to the treatment. 
 The experiment was designed to treat ARPE-19 cells with different 
concentrations of 3-HFA (150, 200, and 250 µM) for 24 hours as shown in Figure 
4. After seeding the cells, the growth media was removed using aspirator then 
3-HFA containing media were added to the wells.  
 
Figure 4   24-well format of a control and 3-HFA treatment in ARPE-19 cells. 
Control 
150 µM 
200 µM 
250 µM 
Control 
3-HPA 
3-HMA 
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2.3 Apoptotic Nuclear Morphological Changes 
 
 Biochemical apoptotic nuclear morphological changes were detected after 
24 hours of 3-HFAs treatment. Apoptotic morphology changes can be visualized 
under microscope and that duration of time is varying based on cell type 
(Saraste, 1999). Control and treated cells were stained with 5 μg /ml DNA-
binding dye, DAPI (4′,6-diamidino-2 phenylindole) for 20-30 minutes at 37 ºC. 
Nuclear images were obtained using epifluorescence microscopy using an EVOS 
FL inverted microscope.  Apoptotic nuclei were counted and presented as a 
percent of total nuclei.  At least 100 cells were counted per well and experiments 
were performed in triplicate.   
 
2.4 Measurement of Caspase 3/7 activity 
 Caspase 3/7 activity was measured by enzymatic fluorophore release 
(Apo one, Promega, TB323) according to the manufacturer’s instruction 
(Promega) and  represented as fold change compared to vehicle treatment, with 
experiments performed in quadruplicate as described (Promega, TB323). Briefly 
caspase substrate and buffer were mixed with 1:100.  After 24 hours of 3-HFA 
treatment in ARPE-19 cells, mixed reagents (caspase substrate and buffer) were 
added. To detect the enzymatic fluorophore release using Synergy-H1 Hybrid 
Reader (BioTek) 
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2.5 Mitochondrial Stress  
 All materials used in this experiment were provided from Agilent Seahorse 
using XF Cell Mito Stress test kit. This experiment was carried out at Biomedical 
and Obesity Research Core (BORC) facility at University of Nebraska-Lincoln. 
Mitochondrial stress experiment was conducted according to Seahorse protocol 
(Meerloo, Kaspers, & Cloos, 2011). The procedure includes cells platting, media 
preparation, stock solutions preparation, and oxygen consumption rate 
measurement. 
 
2.5.1 Platting Cultures and Hydrating Sensor Cartridge 
 ARPE-19 cells were plated in Seahorse XF24 cell culture microplate with 
100 µl/well density mixed with 150 µl/well of DMEM growth media, then cells 
were incubated in 5% CO2 incubator for 8 hours for adherence. The sensor 
cartridge of XF calibration plate was hydrated in 1ml/well of XF calibrant buffer, 
that was premixed and provided from Agilent Seahorse, then the plate was 
stored in non-CO2 incubator overnight for sensor calibration.  
 
2.5.2 Preparing Assay Medium  
 XF base medium was supplemented with the following nutrients (Sigma); 
Pyruvate (1 mM), Glutamine (2 mM) and Glucose (10 mM). The base medium 
was warmed in water bath at 37°C for 5 minutes and the pH was adjusted to 7.4 
and followed by filter sterilization. Cells were rinsed twice with the supplemented 
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base media and stored in non-CO2 incubator for 1 hour prior to the mitochondrial 
stress test. 
  
2.5.3 Preparing Stock Compounds  
 The Seahorse XF Cell Mito Stress Test Kit includes pouches with three 
tubes of Oligomycin (1 μM), Rotenone (0.5 μM), Antimycin (0.5 μM), and FCCP 
(0.5 μM). Each compound was pipetted into 15 mL experiment tube with 3 mL of 
XF base media with the following amounts; Oligomycin (1.24 µL), FCCP (0.67 
µL), and Rotenone/Antimycin (1.5 µL). The previous volumes were calculated 
according to table 5 in Seahorse protocol (Agilent Technologies, 2017). The 
sensor cartridges were loaded with the prepared compounds into the appropriate 
ports as described in the manufacture protocol (Agilent Technologies, 2017; 
Agilent Technologies, 2018).  
 
2.5.4 Running XF Assay and Measurement of Oxygen Consumption Rate 
(OCR) 
 The XF calibration plate was removed from the non-CO2 incubator and 
placed in Agilent Seahorse analyzer instrument tray for calibration for 10 
minutes. After that, calibration plate was replaced by XF cell culture plate to 
obtain oxygen consumption rate (OCR) measurement. The data of OCR for the 
control and treated cells were obtained from Seahorse XF report generator. The 
obtained data were analyzed following Seahorse protocol user guide (Agilent 
Technologies, 2017).  
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2.6 Western Blotting 
2.6.1 Protein Isolation 
 Control and 3-hydroxy fatty acid-treated cells were washed with 3-5 mL of 
cold phosphate buffered saline (PBS).  Then, 1 mL of lysis buffer containing 
HEPES, NaCl, tris—HCl and protease inhibitor mixture was added to the washed 
cells. The cells were scraped with cell scrapper, transferred into microcentrifuge 
tubes and incubated for 40 minutes to complete cell lysis. Cell lysates were 
centrifuged at 12,000 X at 4°C for 20 minutes. After centrifugation, tubes were 
placed on ice and the supernatant was transferred into a new microcentrifuge 
tubes in ice for protein estimation and western blot analysis. 
 
2.6.2 Protein Estimation 
 Total proteins in cell lysates were quantified using bovine serum albumin 
(BSA) as standard using pierce 660nm (ThermoFisher) as described in BIO 
protocol (He, 2011). Briefly, to a 200 µL of Pierce protein assay reagent, 2 μl of 
cell lysate and incubated for 5 minutes, then absorbance was measured at OD 
595 nm using Synergy-H1 Hybrid Reader.  
 
2.6.3 Sodium Dodecyl Sulfate-Polyacrylamide gel electrophoresis (SDS-
PAGE) Gel and Immunoblot analysis: 
 Protein gel electrophoresis is a technique used to separate the proteins 
based on their molecular weights through the electrical field to detect the protein 
of interest. Prior to gel electrophoresis, a 25 μL of molecular weight marker and 
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protein samples were loaded into wells of SDS-PAGE gel (Invitrogen), then 
placed into electrophoresis apparatus to be electrophoresed for 2 hours at 100 V. 
Upon applying the electrical voltage, proteins in the wells migrates down through 
the gel as shown in Figure 5. 
 Next, the gels were transferred to the nitrocellulose membrane (BioRad). 
The proteins were transferred from the gel to a membrane by making transfer 
sandwich stack. The sandwich was placed into a transfer tank that filled with 
transfer buffer (wet method), with 100 V for 1 hour at 4°C. Transferred membrane 
were blocked with 5% milk powder dissolved in TBST for 1 hour at room 
temperature prior to immunoblotting detection. 
 
 
Figurer 5   Schematic representation of SDS-PAGE gel and loading wells. 
 
2.6.4 Immunoblot Detection  
 Transferred membranes were incubated at 4°C overnight with primary 
antibodies against cleaved PARP, Cleaved Caspase 3, and PUMA (1:1000 
dilution in5% milk solution). After that, membrane was washed with TBST three 
 
⁺ ⁻ 
Loaded samples 
Running 
buffer 
Electrophoresis tank 
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times with 10 minutes interval. After washing respective secondary antibody 
conjugated with horse radish peroxidase was added and incubated for 2 hours at 
room temperature. After washing the membrane with TBST three times for 10 
minutes.  Detecting membrane bands was accomplished by adding 1 mL of 
Clarity Western ECL Substrate. Membrane were incubated with 1 ml of solution 
A & B in Clarity Western ECL Substrate kit containing hydrogen peroxide and 
luminol were exposed to autoradiography and chemiluminescent images were 
captured with using ChemiDocTMTouch Imaging System (BIO-RAD).  
 
2.7 Oil Red O Staining 
 A stock solution of oil red O was prepared by dissolving 0.5 g of oil red O 
in 100 mL of isopropanol, then the mixture was filtered through whatman filter 
paper. From the stock solution, 6 mL of oil red O was mixed with 4mL of water. 
After 24 hours of 3-hydroxy fatty acids treatment, cells were fixed with 2mL/wall 
of 10% buffered neutral formalin for 30 minutes, then washed with PBS twice. 
Intracellular lipid droplets in retinal cells were stained with 2mL/ Oil Red O 
solution at room temperature for 20 minutes, then washed four times with distilled 
water. Cells were mounted using Fluoromount-G and coverslips and the images 
were captured using EVOS XL microscope with 40X objective in Dr. Chung’ lab 
in the Department of Nutrition & Health Sciences at the University of Nebraska-
Lincoln facility. 
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2.8 Measuring Cell Survival Using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) Assay  
  To prepare 12 mM stock solution of MTT assay, 1 mL of PBS was added 
to 5 mg of MTT, then it was vortexed. After ARPE-19 cells were treated with 3-
HPA and 3-HMA for 24 hours, the media was removed and 100 μL of MTT 
reagent was added to each well, then incubated for 4 hours.  The Formazan 
formed were with 100 μL of isopropanol then stored at room temperature at dark 
place for 2 hours. The absorbance was measured at OD 570 nm using Synergy-
H1 Hybrid Reader (BioTek). 
 
2.9 Z-VAD and JNK Inhibitors  
ARPE-19 cells were treated with 3-HPA or 3-HMA or vehicle (Veh) with or 
without 50 µM of pan-caspase inhibitor Z-VAD-fmk (Z-VAD) or JNK inhibitor 
(SP600125) for 24 hours. Caspase 3/7 activity and cell survival were measured 
as described above in (E and I).  
 
2.10 Statistical Analysis  
 Data were presented as mean ± standard error of mean (SEM). The 
statistical analysis was performed using one-way analysis of variance (ANOVA) 
with p-value was tested at level 5% * P < 0.05.  Tukey post hoc correction were 
carried out to test the statistical significance and to avoid false positives.  
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3. CHAPTER III: RESULTS 
 
3.1 Results 
3.1.1 Treatment of 3-Hydroxy Palmitic Acids (3-HPA) Decreased 
Mitochondrial Bioenergetics in Retinal Pigmented Epithelial Cells (ARPE-
19) 
To investigate the effect of 3-hydroxy palmitic acids (3-HPA) on 
mitochondrial function in retinal pigmented epithelial cells (ARPE-19), in vitro 
mitochondrial stress test was performed to measure oxygen consumption rate 
(OCR) using Seahorse XF24 Extracellular Flux Analyzer to quantify OCR under 
basal conditions. Treatment of 3-HPA to ARPE-19 cells resulted in a significant 
decrease in mitochondrial OCR detected over 100 minutes Figure 6 (A). Further, 
treatment of 3-HPA to APRE-19 cells showed a significant decrease in basal 
respiration, maximal respiration, adenosine-triphosphate (ATP) production, and 
coupling efficiency compared to vehicle (veh) Figure 6 (B, C, D, and E). Vehicle 
treatment contains equal amounts of isopropanol used to dissolve 3-hydroxy fatty 
acids in 1% BSA containing media for 24 hours. On the other hand, there was a 
non-significant decrease in spare respiratory capacity and proton leak in ARPE-
19 cells treated with 3-HPA compared to vehicle treatment Figure 6 (F and G). 
These data suggest that 3-HPA induces mitochondrial damage and results in 
altered mitochondrial bioenergetics.  
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Figure 6   Mitochondrial bioenergetics functions in ARPE-19 cells treated 
with 3-HPA. A) Oxygen consumption rate (OCR) for 100 minutes in vehicle and 
3-HPA treated ARPE-19 cells. B) Basal respiration (B), Maximal respiration (C), 
ATP production (D), Coupling efficiency (E), Spare respiratory capacity (F) , and 
Proton Leak of ARPE-19 cells treated with 3-HPA and compared with vehicle 
ARPE-19 cells, respectively* indicates P-value with different level of significance 
compared to vehicle treatment, *(<0.05). ** (<0.01), and ***(<0.001). The data is 
represented mean ± SEM from five independent experiments, n=5.The statistical 
significance of the observed differences were obtained by analysis of variance 
(ANOVA) and Tukey post-hoc test. 
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3.1.2 3-Hydroxy Fatty Acids (3-HFAs) Induce Retinal Pigmented Epithelial 
Cell (ARPE-19) Lipoapoptosis  
 To examine whether treatment of 3-HFA to retinal cells induce 
lipoapoptosis; we assessed the biochemical characteristics nuclear 
morphological changes of lipoapoptosis using DNA-binding dye, 4’, 6-diamidino-
2-phenylindole (DAPI) and epifluorescence microscope. ARPE-19 cells treated 
with 3-HPA or 3-HMA showed increased characteristic nuclear morphological 
changes like nuclear fragmentation, pyknosis or chromatin condensation and cell 
shrinking compared to vehicle treated cells. The representative phase contrast 
image and DAPI stained fluorescent image of ARPE-19 cells treated with vehicle 
or 3-HPA (100-250 μM) were showed in Figure 7. Representative images of 
retinal cells were with 3-HMA treatment (100-250 μM) were showed in Figure 8 
.We observed an increase in DAPI staining with increasing concentration of 3-
HPA (100-250 μM) shown in Figure 7 (C, D, E, F, G and H) and with increasing 
concentration of 3-HMA compared to vehicle (100-250 μM) suggesting retinal cell 
lipoapoptosis Figure 8 (C, D, E, F, G and H). There was a significant increase in 
the percent apoptotic nuclei in 3-HPA or 3-HMA treated cells compared to vehicle 
Figure 9 (A and B).  Further, we measured caspase 3/7 activity by using 
fluorophore-tagged caspase substrate and expressed as fold change of caspase 
3/7 activity over vehicle treatment. Treatment of 3-HPA or 3-HMA (250 μM) 
significantly increased caspase 3/7 activity compared to vehicle treated cells 
Figure 9 (C and D). These data suggest that 3-HFAs induces retinal pigment 
epithelial cell lipoapoptosis.    
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Evidence for cell death in APRE-19 cells with 3-HFA treatment 
Another way to test cell death is by measuring nicotinamide adenine 
dinucleotide (NAD)-dependent cellular oxidoreductase enzymes. These enzymes 
reflect the metabolic activity of the cells and can reduce the tetrazolium dye, 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). We measured 
the MTT reduction and formazan formation as an indicator of cell survival in 
APRE-19 cells with 3-HPA or 3-HMA treatment and expressed as percent cell 
survival. The 3-HMA (100-250 μM) treated cells showed a significant decrease in 
percent cell survival compared to the vehicle treated cells shown in Figure 9 (E). 
Also, treatment of 3-HPA (100-250 μM) significantly decreased the percent cell 
survival in ARPE-19 cells compared to vehicle treated cells shown in Figure 9 
(F). The reduction in the cell survival with 3-HFA treatment was due to the toxic 
role of 3-HFA in altering mitochondrial functions. These data suggest that 3-HFA 
induces mitochondrial abnormalities and alters mitochondrial cellular and 
metabolic functions in ARPE-19 cells. 
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Figure 7 Representative phase contrast and fluorescent DAPI stained live 
cell images of ARPE-19 cells with 3-HPA treatment. This representative figure 
shows that 3-hydroxy palmitic acids (3-HPA) induced nuclear morphological 
changes in retinal pigment epithelial cell (ARPE-19) lipoapoptosis. (A and B) are 
vehicle cells. (C-H) are ARPE-19 cells were treated with different concentrations 
of 3-HPA (100, 200, and 250 µM). Scale bar represents 200 μM. 
Vehicle 
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Figure 8 Representative phase contrast and fluorescent DAPI stained live 
cell images of ARPE-19 cells with 3-HMA treatment. This representative 
figure shows that 3-hydroxy myristic acids (3-HMA) nuclear morphological 
changes in in retinal pigment epithelial cell (ARPE-19) lipoapoptosis. (A and B) 
Vehicle Vehicle 
3-HMA-100 µM 3-HMA-100 µM 
3-HMA-200 µM 3-HMA-200 µM 
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(G) (H) 
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are vehicle cells. (C-H) are ARPE-19 cells were treated with different 
concentrations of 3-HMA (100, 200, and 250 µM). Scale bar represents 200 μM. 
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Figure 9 Evidence for cell death in APRE-19 cells with 3-HFA treatment. A) 
Apoptotic nuclei percent for ARPE-10 cells treated with different concentrations 
of 3-hydroxy myristic acid (3-HMA) (100- 250 µM) and B) Cells treated with 3-
hydroxy palmitic acid (3-HPA) (100-250 µM). C) Caspase 3/7 activity represented 
as fold change in ARPE-19 cells treated with 3-HMA D) cells treated with 3-HPA. 
E and F) Percent cell survival of ARPE-19 with different concentrations of 3-HMA 
or 3-HPA treatment. * indicates P-value with different level of significance, 
*(<0.05). ** (<0.01), and ***(<0.001). The differences in the apoptotic changes 
reached a statistical significance by obtaining that using ANOVA and Tukey test. 
 
 
3.1.3 Saturated Free Fatty Palmitic Acid (PA) and Myristic Acid (MA) Did Not 
Induce Retinal Pigment Epithelial Cell Lipoapoptosis 
 Similarly, ARPE-19 cells were treated with palmitic acid (PA) or myristic 
acid (MA) with different concentrations like 100, 150, 200 and 250 μM to 
emphasize the role of saturated free fatty acids in cell apoptosis. Treatment of 
PA or MA did not increase the percent retinal cell lipoapoptosis compared to 
vehicle treated cells shown in Figure 10 and 11 (A, B, C, D, E, F, G, H, I, and J). 
The percent of apoptotic nuclei and caspase 3/7 activity did not show any 
difference in apoptosis in vehicle and retinal cells were treated with PA or MA 
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shown in Figure 12 (A, B, C and D). Together, the treatment of saturated free 
fatty acids in retinal cells (ARPE-19) did not induce lipoapoptosis. 
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Figure 10 Representative phase contrast and fluorescent DAPI stained live cell 
images of ARPE-19 cells with MA treatment. This representative figure shows that 
myristic acids (MA) did not increased staining of DAPI suggesting no change in 
characteristics of nuclear morphological changes in in retinal pigmented epithelial cell 
(ARPE-19) lipoapoptosis. (A and B) are vehicle cells. (C, D, E, F, G, H, I and J) ARPE-
19 cells were treated with different concentrations of MA (100, 150, 200, and 250 µM). 
Scale bar represents 200 μM.  
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Figure 11 Representative phase contrast and fluorescent DAPI stained live 
cell images of ARPE-19 cells with PA treatment. This representative images 
show that palmitic acids (PA) did not increase staining of DAPI suggesting no 
change in characteristics of nuclear morphological changes in in retinal pigment 
epithelial cell (ARPE-19) lipoapoptosis. (A and B) vehicle treated cells. (C, D, E, 
f, G, H, I and J) ARPE-19 cells were treated with different concentrations of PA 
(100, 150, 200, and 250 µM). Scale bar represents 200 μM.  
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Figure 12 Apoptotic nuclei percent for ARPE-10 cells treated with different 
concentrations of myristic acid (MA) (100-250 µM) (A) and ARPE-19 cells treated 
with different concentrations of palmitic acid (PA) (100-250 µM) (B). Caspase 3/7 
activity in ARPE-19 cells treated with MA (C) and PA (D). * indicates P-value with 
different level of significance, *(<0.05). ** (<0.01), and ***(<0.001). 
 
3.1.4 Biochemical Hallmark of Apoptosis  
 Cell lysates of retinal cells treated with 3-HPA or 3-HMA were collected 
after 12, 18, and 24 hours of treatment. Western analysis showed that there was 
a dramatic increase in the expression of cleaved PARP in both 3-HMA and 3-
HPA treated cells compared to vehicle treatment shown in Figure 13. Further, 
we observed that the levels of pro-apoptotic BH3 domain containing proteins, 
PUMA (p53 upregulated modulator of apoptosis) were upregulated after 12-24 
hours of 3-HPA or 3-HMAs treatment in ARPE-19 cells. We have observed 
caspase 3/7 activation with 3-HPA or 3-HMA treatment in retinal cells. 
Immunoblot analysis of active caspase 3 or cleaved-caspase 3 were increased in 
both 3-HMA and 3-HPA treated cells after 12-24 hours compared to vehicle 
treated retinal cells shown in Figure 13. Actin was used for control loading and 
showed no change among different time points of treatment and vehicle treated 
cells. These data suggest that the activation of pro-apoptotic proteins and the 
initiation of intrinsic pathway of apoptosis in 3-HPA or 3-HMA treated ARPE-19 
cells. 
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Figure 13 Immunoblot analysis of Cleaved PARP, PUMA, Cleaved Caspase 3, 
and Actin in vehicle and 3-HPA/3-HMA treated ARPE-19 cells. Vehicle cells were 
isopropanol treatment and 3-HPA (250 µM) or 3-HMA (250 µM) treated cell 
lysates were analyzed after 12, 18, and 24 hours of treatment. 
 
 
 
3.1.5 Palmitoleic Acid (PO) Protects Against 3-HFA-Induced Lipotoxicity 
 Palmitoleic acid (PO) is a mono-unsaturated omega-7 fatty acid and has 
been shown to be protective against free fatty acid-induced hepatocyte and 
cholangiocyte lipotoxicity (Yang, H., Miyahara, & Hatanaka, 2011); (Yang, Z. H. 
et al., 2011). To determine the beneficial role of PO in protecting ARPE-19 cells 
against the lipotoxicity, we co-treated 200 μM of PO with 3-HPA or 3-HMA for 24 
hours. Similar to data presented in Figure 9 (A and B), we observed that 3-HPA 
or 3-HMA increased percent apoptotic nuclei compared to vehicle treatment and 
the cotreatment of PO and 3-HPA or 3-HMA showed a dramatic decrease in 
percent apoptotic nuclei in retinal pigment epithelia cell shown in Figure 14 (A 
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and B). Similarly, cotreatment of PO and 3-HFAsalso reduced caspase 3/7 
activity compared to cells treated with 3-HPA or 3-HMA alone shown in Figure 
14 (C and D). In addition, percent cell survival was significantly protected when 
ARPE-19 cells were co-treated with 3-HPA or 3-HMA with PO, compared to 3-
HPA or 3-HMA alone, which decreases cell survival shown in Figure 14 (E and 
F). These data suggest that PO protects against 3-HFA-induced retinal cell 
lipoapoptosis.  
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Figure 14   Apoptotic cell death and caspase activation in ARPE-19 cells 
treated with 3-HPA or 3-HMA along with palmitoleate. Apoptotic nuclei 
percent for ARPE-19 cells treated with 3-HMA and PO (A) and cells treated with 
3-HPA and PO (B). Caspase 3/7 activation in ARPE-19 cells treated with 3-HMA 
and PO (C) and cells treated with 3-HPA and PO (D). Percent cell survival of 
ARPE-19 cells with 3-HMA (E) or 3-HPA (F) with and without palmitoleate (PO). 
Data represents mean ± SEM from five independent experiments, n=5. * 
indicates P-value with different level of significance of 3-HPA or 3-HMA 
compared to vehicle, *(P<0.05). ** (P<0.01), and ***(P<0.001). #P>0.05 
compared to 3-HPA or 3-HMA.  
 
 
3.1.6 Retinal Cells Accumulate Lipid Droplets with 3-HPA or 3-HMA 
Treatment 
 To investigate whether retinal cells accumulate lipid droplets, ARPE-19 
cells were stained with oil red O’ after cells were treated with 250 μM of 3-HPA or 
3-HMA for 24 hours with and without palmitoleate (PO). We observed that 
ARPE-19 cells with 3-HPA or 3-HMA treatment accumulated lipid droplets 
comparing to vehicle treated cells shown in Figure 15. The lipid droplets 
0
20
40
60
80
100
120
Veh 3-HMA  3-HMA +
PO
C
e
ll
 S
u
rv
iv
a
l 
(%
) 
 
Treatment
3-HMA      
*
0
20
40
60
80
100
120
Veh 3-HPA 3-HPA +
PO
C
e
ll
 S
u
rv
iv
a
l 
(%
) 
 
Treatment
3-HPA      
*
E F 
51 
 
accumulation is reduced in retinal cells co-treated with PO and 3-HPA or 3-HMA 
shown in Figure 15. We also quantitated Oil red O’ staining in retinal cells with 3-
HFA treatment by measure the absorbance of stained cells at 490 nm (Fei Z et 
al, 2011).  ARPE-19 cells treated with 3-HPA or 3-HMA showed increased Oil red 
O staining and co-treatment of PO with 3-HPA or 3-HMA significantly reduced 
lipid accumulation in retinal cells shown in Figure 16 (A and B). These data 
suggest that palmitoleate protects against 3-HFA-induced lipotoxicity in retinal 
cells by decreasing the accumulation of lipid droplets. Further studies are needed 
to elucidate the mechanism of PO preventing lipid droplet accumulation in retinal 
cells. 
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Figure 15   Lipid droplet accumulation for ARPE-19 cells. Cells stained with 
Oil red O’ assay visualized under light microscope. Control cells were treated 
with Vehicle (A) and Palmitoleate (B). Retinal cells with 250 μM of 3-HMA (C) 
and 3-HPA treatment (E) for 24 hours showed increased Oil red ‘O’ staining. Co-
treatment of palmitoleate (PO) with of 250 µM 3-HPA or 3-HMA (D and F) 
Vehicle  PO-200 µM 
3-HPA-250 µM 3-HPA+PO  
3-HMA+PO 3-HMA-250 µM 
(A) 
(D) 
(B) 
(C) 
(E) (F) 
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resulted in decreased Oil red ‘O’ staining. The images are representative images 
from three independent experiments, n=3. 
   
  
  
Figure 16   Oil red O’ assay absorbance in ARPE-19 cells.  ARPE-19 cells 
treated with only 3-HMA (250 µM) and both 3-HMA (250 µM) and PO (200 µM) 
(A). Cells treated with 3-HPA (250 µM) alone and co-treated with 3-HPA (250 
µM) and PO (200 µM) (B). * indicates P-value with different level of significance 
of 3-HPA or 3-HMA compared to vehicle, *(<0.05). ** (<0.01), and ***(<0.001). # 
indicates P-value for 3-HPA or 3-HMA with PO compared to 3-HPA or 3-HPA   
   
3.1.7 3-HFA-Induces Retinal Cell lipoapoptosis is c-Jun N-terminal Kinase 
Activation. 
To determine the critical role of c-Jun N-terminal kinase (JNK) in 3-HFA-
induced ARPE-19 lipoapoptosis; we used small molecule inhibitors of JNK 
(SP600125, JNKi).  ARPE-19 cells were treated with 3-HPA or 3-HMA alone and 
co-treated with JNKi. First, we measured the activation of caspase in cells 
treated with only 3-HFAs and co-treatment of 3-HFAs with JNK inhibitor. Both 3-
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HMA and 3-HPA treatment increases caspase 3/7 activation in retinal cells and 
co-treatment of 3-HFAs with SP600125 (JNK inhibitor) resulted in a significant 
protection against 3-HFAs induced caspase 3/7 activation Figure 17 (A and B). 
Decreased percent cell survival of retinal cells with 3-HPA or 3-HMA treatment 
after 24 hours were significantly prevented with the cotreatment of JNK-i Figure 
17 (C and D). 
 
3.1.8 3-HFA Induces Retinal Cell Lipoapoptosis is Caspase Dependent 
To determine the critical role of caspase in 3-HFA-induced ARPE-19 
lipoapoptosis; we used pan-caspase inhibitor (Z-VAD fmk).  ARPE-19 cells were 
treated with 3-HPA or 3-HMA alone and co-treated with Z-VAD. First, we 
measured the activation of caspase in cells treated with only 3-HFAs and co-
treatment of 3-HFAs with caspase inhibitor. We observed that co-treatment of 3-
HFAs with Z-VAD-fmk decreased the 3-HFA-induced caspase activation in 
ARPE-19 cells Figure 18 (A and B).  Inhibition of caspase activity using Z-VAD 
also protected 3-HFA-induced apoptosis ARPE-19 cells as evidenced by an 
increase in percent cell survival with 3-HFA and Z-VAD co-treated retinal cells 
Figure 18 (C and D). 
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Figure 17 Caspase 3/7 activity and percent cell survival in ARPE-19 cells 
treated with JNK-i. Caspase 3/7 activity were measured when cells were treated 
with 3-HMA and co-treated with 3-HMA and JNK inhibitor (SP600125, JNKi) (A) 
or treated with only 3-HPA or co-treated with 3-HPA and JNK-i. (B). Percent cell 
survival were measured when cells were treated with only 3-HMA or co-treated 
with 3-HMA JNKi (C) and only 3-HPA and co-treated with 3-HPA and JNKi (D). 
Data represent mean ± SEM from five independent experiments, n=5. *indicates 
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P-value with different level of significance of 3-HPA or 3-HMA compared to 
vehicle (veh), *(<0.05). ** (<0.01), and ***(<0.001). # P<0.05 compared to 3-HMA 
or 3-HPA treatment  
 
 
 
 
Figure 18 Caspase 3/7 activity and percent cell survival in ARPE-19 cells 
treated with Z-VAD. Caspase 3/7 activity were measured when cells were 
treated with 3-HMA and co-treated with 3-HMA and caspase inhibitor (Z-VAD 
fmk) (A) or treated with only 3-HPA or co-treated with 3-HPA and Z-VAD (B). 
Percent cell survival were measured when cells were treated with only 3-HMA or 
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co-treated with 3-HMA Z-VAD (C) and only 3-HPA and co-treated with 3-HPA 
and Z-VAD (D). Data represent mean ± SEM from five independent experiments, 
n=5. *indicates P-value with different level of significance of 3-HPA or 3-HMA 
compared to vehicle (veh), *(<0.05). ** (<0.01), and ***(<0.001). # P<0.05 
compared to 3-HMA or 3-HPA treatment  
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4. CHAPTER IV: DISCUSSION, CONCLUSION, AND FUTURE 
DIRECTIONS 
 
4.1 Discussion  
 This study confirms the lipotoxic role of 3-hydroxy fatty acids (3-HFAs) like 
3-hydroxy palmitic acids (3-HPA) and 3-hydroxy myristic acids (3-HMA) in 
inducing lipoapoptosis in retinal pigmented epithelial cells (ARPE-19). 
Accumulation of 3-HFAs are involved in children with LCHAD deficiency leading 
to develop pathophysiology such as retinopathy, cardiovascular disease, and 
muscle atrophy. Retinopathy is a widely associated with mitochondrial 
dysfunctions, however, there is a gap in knowledge on the mechanism of 3-HFA-
induced retinal pigment epithelial cell lipotoxicity. The main goal of the present 
study is to test lipotoxicity in retinal cells and we used a normal human 
immortalized retinal pigmented epithelial cell, ARPE-19, in vitro. Lipoapoptosis is 
known as programmed cell death that is caused due to the exposure of high 
concentration of fatty acids. Apoptosis due to caspase activation and 
mitochondrial alteration, which are characterized by oxidative stress due to 
accumulating toxic free fatty acids in the circulation during obesity and metabolic 
syndrome has been well established (Wajner & Umpierrez, 2016) . We 
characterized retinal pigmented epithelial cell features and evaluated caspases 
activity, mitochondrial functions, lipid droplets, and biochemical hallmarks of 
apoptosis with 3-HFA exposure. To examine all these characteristics, cells were 
treated with 3-HFAs including 3-hydroxy palmitic acids (3-HPA) or 3-hydroxy 
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myristic acids (3-HMA) to mimic and simulate pathophysiological condition in 
LCHAD patient’s blood circulation. Patients with defective fatty acid oxidation 
metabolism especially who are deficient in the enzyme long-chain hydroxy acyl-
CoA dehydrogenase (LCHAD), can accumulate metabolites and substrates such 
as saturated free fatty acids and hydroxy fatty acids. Here we hypothesize that 
the retinal cell apoptosis could contribute and result in retinopathy observed in 
LCHAD deficient patient. In the present study, we demonstrated that 3-HPA or 3-
HMA exposure to retinal pigment epithelial cells resulted in retinal cell 
lipoapoptosis. Apoptosis can leads to mitochondrial stress, caspases activation, 
and lipid accumulation.   
Lipotoxic role of 3-HFAs in inducing lipoapoptosis is in agreement with our 
unpublished work that has shown the accumulation of 3-HFAs including 3-HMA 
or 3-HPA induces hepatocyte lipoapoptosis leading to apoptosis and caspase 
activation (Natarajan, S. K. & Ibdah, 2018). Additionally, previous study 
conducted on human disease model created from a pluripotent stem cell (hiPSC) 
differentiation to retinal cells demonstrates that retinal pigmented epithelial cells 
developed pathogenic changes with retinal characteristics and nuclear 
morphology suggesting the apoptosis (Padmini et al., 2015).  
 Mitochondria are the major site for energy metabolism and mitochondrial 
mediated activation of intrinsic pathway of apoptosis is characterized with 
mitochondrial permeabilization and release of cytochrome C resulting in the 
formation of apoptosome and activation of caspases (Natarajan SK, 17 February 
2012) . Our previous research using placenta from patients with acute fatty liver 
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of pregnancy (AFLP) showed oxidative stress in the placental subcellular 
organelle and maternal systemic (Natarajan, S. et al., 2010; Natarajan, S., 
Thangaraj, Eapen, Ramachandran, & Balasubramanian, 2011; Natarajan, S. K., 
Eapen, Pullimood, & Balasubramanian, 2006) . Defects in placental 
mitochondrial fatty acid oxidation can channel the fatty acids to peroxisomal β-
oxidation and microsomal omega-oxidation. Increased peroxisomal β-oxidation 
would result in the generation of hydrogen peroxide, which could: 1) damage 
subcellular organelles; 2) alter redox homeostasis; 3) damage cellular redox-
sensitive protein function; and 4) contribute to the cell death and disease 
development. Further, placental mitochondria isolated from patients with AFLP 
showed mitochondrial dysfunction and the levels of antioxidants such as 
tocopherol and retinol were decreased in the systemic circulation of AFLP 
patients compared to controls suggesting oxidative stress in maternal systemic 
circulation in patients with AFLP. Further, we have shown animals treated with 
valproate, an inhibitor of liver mitochondrial β-oxidation, showed hepatic 
mitochondrial dysfunction, oxidative stress and microvesicular steatosis in the 
liver suggesting that a blockage in mitochondrial β-oxidation would induce 
hepatic mitochondrial dysfunction and oxidative stress in the liver (Natarajan, S. 
et al., 2010; Natarajan, S. et al., 2011; Natarajan, S. K. et al., 2006). Similar to 
the placental and liver cells; in the present work retinal cells exposed to 3-HPA 
resulted significant alteration in the mitochondrial bioenergetics and functions. 
Mitochondrial dysfunction and damage results in alteration to mitochondrial 
respiration with the exposure of lipotoxic 3-HFA metabolites.  In ARPE-19 cells 
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that were treated with 3-HPA, there was a significant decrease in the ATP 
production, basal respiration and spare respiratory capacity, and coupling 
efficiency. All these abnormalities resulted to compensate the stress that was 
induced by the accumulation of 3-HFA. The findings suggest that mitochondrial 
stress is the mechanism that contributes to the 3-HFA-induced ARPE-19 cell 
death. Similar to our findings, a recent study showed that defective mitochondria 
resulted in altering the respiratory chain and coupling efficiency which increase 
reactive oxygen species (ROS) (Radek, Marco, & Heinz, 2014).  
 Retinal pigment epithelial cells (RPE) functions to maintain recycling of 11-
cis-retinaldehyde, absorbs excess light and contributes to the phagocytosis of 
photoreceptors fragments (Tivadar O., Palczewska G., Palczewski K., 2011 May 
12). RPE cells also store retinyl esters in retinosomes and excess fatty acids as 
lipid droplets (Brink. D. et al., 2018). Lipid droplets accumulation in RPE can 
impair normal cell signaling leading to cellular dysfunction and apoptotic cell 
death (Meyer et al., 2011). Similarly, ARPE-19 cells have been shown to 
accumulate lipid droplets (Chena et al., 2019) .  It has also been shown that 
retinal cells can accumulate lipid droplets during LCHAD deficiency (Chena et al., 
2019) Further free fatty acid and high glycose exposure during obesity and 
metabolic syndrome has also been shown to increased lipids droplets 
accumulation in retinal pigment epithelial cells (Chena et al., 2019). The retinal 
dysfunction due to free fatty acid and high glucose exposure to retinal cells has 
been demonstrated as the mechanism for the progression of diabetic retinopathy  
which resulted in retinal atrophy (Chena et al., 2019).  Rudolf et al., showed that 
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retinal pigment epithelial cells can also accumulate lipid droplets with aging in 
human retina through accumulations of lipoproteins particles resulting in age-
related macular degeneration (Rudolf & Curcio, 2009). Further, it has been 
shown that overexpression of fatty acid transport protein (FATP) in retinal cells of 
drosophila and mice enhanced lipid droplets accumulation (Brink. D. et al., 2018). 
Under normal conditions, these lipid droplets have a beneficial effect on the 
retinal cells and photoreceptors. However, under vitamin A deficiency diet, the 
accumulation lipids droplets were toxic which disturbed the photoreceptors 
homeostasis (Van Den et al., 2018). 
 Our lab has previously shown that forkhead family of transcription factor 
class O3 (FoxO3) is activated in hepatocytes that were treated with 3-HFAs 
(Natarajan, S. K. et al., 2017) . The activation of FoxO3 is associated with cell 
death signaling, because FoxO3 can transcriptionally upregulates the pro-
apoptotic protein, like BIM, PUMA and NoxA which can induce lipoapoptosis 
(Natarajan, S. K. et al., 2017). In the present study, we observed biochemical 
evidence of apoptosis such as increased levels of PUMA in ARPE-19 cells 
treated with 3-HPA or 3-HMA. However, the role of FoxO3 activation and the 
critical role of pro-apoptotic protein, PUMA in retinal lipoapoptosis requires 
further investigation. The increased expression of pro-apoptotic BH3 domain 
containing protein, PUMA indicates the activation of intrinsic pathway of 
apoptosis. Increased levels of PUMA can act against anti-apoptotic proteins like 
BCL2 and MCL1. The expression of anti-apoptotic proteins in retinal pigment 
epithelial cells with 3-HFAs requires further investigation. Caspase 3/7 enzyme 
63 
 
activity is responsible for cleaving downstream caspase substrates such as poly 
adenosine-ribose polymerase (PARP). The increased levels of caspase 
substrate, cleaved PARP and cleaved caspase 3, are key markers for the late 
phase of the apoptosis were evident in retinal cells exposure to 3-HFA. In 
addition to caspase substrate, inhibition of caspases using small molecular 
inhibitor blocked 3-HFA-induced lipoapoptosis in retinal cells suggestions the 
critical role of caspase activation during retinal pigment cell lipoapoptosis. In 
summary, apoptotic hallmarks were evident when ARPE-19 cells were exposed 
to higher concentrations of 3-HPA or 3-HMA, suggesting the involvement of 
retinal cell lipoapoptosis in the development of retinopathy in patients with 
LCHAD deficiency. 
 In the present study, we proposed a dietary nutrient intervention to protect 
against 3-HFA-induced lipotoxicity in retinal cells with palmitoleic acid (PO) 
supplementation. PO is an omega 7-mono unsaturated fatty acids and PO has 
been shown to protect against saturated free fatty acid-induced hepatocyte and 
cholangiocyte lipoapoptosis (Akazawa, 2010). PO treatment has been shown to 
abolish palmitate-induced endoplasmic reticulum (ER) stress response, JNK 
activation, mitochondrial pro-apoptotic mediators, and lipotoxicity (Akazawa, 
2010) . Further, supplementation of palmitoleate has been shown to unalter the 
expression of stearoyl CoA-desaturase1 (SCD1), an enzyme that can convert 
palmitate into palmitoleate, however palmitoleate (PO) increased lipid droplets 
accumulation and decreases the lipotoxicity of saturated FFAs in hepatocytes 
(Akazawa, 2010) . In addition, decreased expression of SCD1 were found to 
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enhance palmitate-induced trophoblast lipotoxicity (Yang, C., Lim, Bazer, & 
Song, 2018). Nevertheless, the in vivo effect of PO on retinopathy still needed to 
be elucidated. PO is involved in many processes associated with cell function, 
acts as anti-apoptotic fatty acid, and improves lipid profile in obese mice (Yang, 
H., Miyahara, & Hatanaka, 2011). Further, supplementation of PO significantly 
reduces the hepatic triglyceride levels and lipid droplets accumulation in the liver 
of diabetic mice (Yang, H. et al., 2011). In the present study, our data 
demonstrated the positive role of PO in protecting against lipoapoptosis. 
Additionally, lipid droplets accumulation in ARPE-19 has been decreased 
significantly when cells treated with PO compared to 3-HFAs treatment. Also, 
palmitoleate protects against 3-HFA-induced retinal cell lipoapoptosis. We 
observed that treatment of JNK-inhibitor protected against 3-HFA induced retinal 
lipoapoptosis, these data suggest that JNK plays a critical role in retinal 
lipoapoptosis. Saturated free fatty acids are known to active JNK-dependent 
hepatocyte lipoapoptosis (Malhi. H., Bronk. S., Werneburg. N., and Gores. G., 
2006). However, our lab has previously showed that JNK is not critical for 
cholangiocyte lipoapoptosis (Natarajan, S. K. et al., 2014). Here, we speculate 
that PO protection could involve prevention of JNK activation, further studies are 
needed to demonstrate the role of JNK signaling with PO supplementation. Chen 
et al., showed that JNK could transitionary upregulates the expression of PUMA 
protein during cell death process (Chena et al., 2019). However, it is still not clear 
whether treatment with PO could alter the transcriptional activity of JNK for the 
protection against retinal lipoapoptosis and requires further investigation.  
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Further, demonstrating the retinal cell lipoapoptosis in animal models of LCHAD 
deficiency and dietary supplementation of palmitoleate protecting against retinal 
injury, retinopathy and lipoapoptosis requires further investigation.  
 
 
4.2 Conclusions and Future Directions 
 In conclusion, the data from the present study show that 3-hydroxy fatty 
acids can induce lipoapoptosis in retinal pigment epithelial cells. The 
mechanisms are involved in lipoapoptosis were; caspase 3/7 activation, 
mitochondrial dysfunction, and activation of pro-apoptotic protein PUMA. All 
these events together support the hypothesis that 3-HFA induces lipotoxicity in 
retinal cells in vitro. Also, we show evidence for palmitoleate protection against 
3-HFA induced lipotoxicity. The data presented in this study were from ARPE-19 
cell line. Our next steps are to use LCHAD knockdown animal and confirm the 
lipotoxic role of 3-hydroxy fatty acids in inducing the retinal damage and 
retinopathy. In addition, we would also like to use CRISPR/Cas9 system to 
introduce pathogenic mutation in LCHAD encoding gene, HADHA in retinal cells 
to test retinal cell lipoapoptosis. Further investigations are also required to 
understand the mechanism of PO in protecting against 3-HFA-induced retinal cell 
lipotoxicity.  
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